Safety 2 years [clinicaltrials_resource:fdee50d0abc2a0360468afe73c5daba3]
Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.
Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.
After completion of study treatment, patients are followed every 3 months
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Safety 2 years [clinicaltrials_resource:fdee50d0abc2a0360468afe73c5daba3]
Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.
Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.
After completion of study treatment, patients are followed every 3 months
Bio2RDF identifier
fdee50d0abc2a0360468afe73c5daba3
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:fdee50d0abc2a0360468afe73c5daba3
measure [clinicaltrials_vocabulary:measure]
time frame [clinicaltrials_vocabulary:time-frame]
description
Patients receive sialyl Lewisª ...... ts are followed every 3 months
identifier
clinicaltrials_resource:fdee50d0abc2a0360468afe73c5daba3
title
Safety 2 years
@en
type
label
Safety 2 years [clinicaltrials_resource:fdee50d0abc2a0360468afe73c5daba3]
@en